Mostrar el registro sencillo del ítem

dc.contributor.authorKliemann, Nathalie
dc.contributor.authorSánchez Pérez, María José 
dc.date.accessioned2022-09-02T09:08:04Z
dc.date.available2022-09-02T09:08:04Z
dc.date.issued2022-07-01
dc.identifier.citationNathalie Kliemann... [et al.]. Metabolically Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 1 July 2022; 31 (7): 1359–1367. [https://doi.org/10.1158/1055-9965.EPI-22-0160]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/76477
dc.description.abstractBackground: Obesity is a risk factor for endometrial cancer but whether metabolic dysfunction is associated with endometrial cancer independent of body size is not known. Methods: The association of metabolically defined body size phenotypes with endometrial cancer risk was investigated in a nested case–control study (817 cases/ 817 controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC). Concentrations of C-peptide were used to define metabolically healthy (MH; <1st tertile) and metabolically unhealthy (MU; ≥1st tertile) status among the control participants. These metabolic health definitions were combined with normal weight (NW); body mass index (BMI)<25 kg/m2 or waist circumference (WC)<80 cm or waist-to-hip ratio (WHR)<0.8) and overweight (OW; BMI≥25 kg/m2 or WC≥80 cm or WHR≥0.8) status, generating four phenotype groups for each anthropometric measure: (i) MH/NW, (ii) MH/OW, (iii) MU/ NW, and (iv) MU/OW. Results: In a multivariable-adjusted conditional logistic regression model, compared withMH/NWindividuals, endometrial cancer risk was higher among those classified as MU/NW [ORWC, 1.48; 95% confidence interval (CI), 1.05–2.10 and ORWHR, 1.68; 95% CI, 1.21– 2.35] and MU/OW (ORBMI, 2.38; 95% CI, 1.73–3.27; ORWC, 2.69; 95% CI, 1.92–3.77 and ORWHR, 1.83; 95% CI, 1.32–2.54). MH/OW individuals were also at increased endometrial cancer risk compared with MH/NW individuals (ORWC, 1.94; 95% CI, 1.24–3.04). Conclusions: Women with metabolic dysfunction appear to have higher risk of endometrial cancer regardless of their body size. However, OW status raises endometrial cancer risk even among women with lower insulin levels, suggesting that obesityrelated pathways are relevant for the development of this cancer beyond insulin. Impact: Classifying women by metabolic health may be of greater utility in identifying those at higher risk for endometrial cancer than anthropometry per se.es_ES
dc.description.sponsorshipWorld Health Organizationes_ES
dc.description.sponsorshipDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College Londones_ES
dc.description.sponsorshipDanish Cancer Societyes_ES
dc.description.sponsorshipLigue nationale contre le canceres_ES
dc.description.sponsorshipInstitut Gustave Roussyes_ES
dc.description.sponsorshipMutuelle Generale de l'Education Nationalees_ES
dc.description.sponsorshipInstitut National de la Sante et de la Recherche Medicale (Inserm)es_ES
dc.description.sponsorshipDeutsche Krebshilfees_ES
dc.description.sponsorshipHelmholtz Associationes_ES
dc.description.sponsorshipGerman Institute of Human Nutrition PotsdamRehbruecke (DIfE)es_ES
dc.description.sponsorshipFederal Ministry of Education & Research (BMBF)es_ES
dc.description.sponsorshipFondazione AIRC per la ricerca sul cancroes_ES
dc.description.sponsorshipCompagnia di San Paoloes_ES
dc.description.sponsorshipConsiglio Nazionale delle Ricerche (CNR)es_ES
dc.description.sponsorshipDutch Ministry of Public Health, Welfare and Sports (VWS)es_ES
dc.description.sponsorshipNetherlands Cancer Registry (NKR)es_ES
dc.description.sponsorshipLK Research Fundses_ES
dc.description.sponsorshipDutch Prevention Funds Netherlands Organization for Scientific Research (NWO)es_ES
dc.description.sponsorshipWorld Cancer Research Fund (WCRF-ERC) 232997es_ES
dc.description.sponsorshipNetherlands Governmentes_ES
dc.description.sponsorshipHealth Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII)es_ES
dc.description.sponsorshipJunta de Andaluciaes_ES
dc.description.sponsorshipPrincipality of Asturiases_ES
dc.description.sponsorshipBasque Governmentes_ES
dc.description.sponsorshipRegional Government of Murciaes_ES
dc.description.sponsorshipRegional Government of Navarraes_ES
dc.description.sponsorshipCatalan Institute of OncologyICO (Spain)es_ES
dc.description.sponsorshipSwedish Cancer Society Swedish Research Counciles_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.description.sponsorshipCounty Council of Skanees_ES
dc.description.sponsorshipCounty Council of Vasterbotten (Sweden)es_ES
dc.description.sponsorshipCancer Research UK 14136 C8221/A29017 C19335/A21351es_ES
dc.description.sponsorshipUK Research & Innovation (UKRI)es_ES
dc.description.sponsorshipMedical Research Council UK (MRC)es_ES
dc.description.sponsorshipEuropean Commission 1000143 MR/M012190/1es_ES
dc.language.isoenges_ES
dc.publisherAmerican Association for Cancer Researches_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleMetabolically Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1158/1055-9965.EPI-22-0160
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional